1-4 of 4
Michelle Velasquez
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia

Fadi Haddad, Hagop Kantarjian, Nicholas J. Short, Marina Konopleva, Nitin Jain, Farhad Ravandi, Naval Daver, Yesid Alvarado, Koichi Takahashi, Guillermo Garcia-Manero, Michelle Velasquez, Rebecca Garris, Elias J. Jabbour
Journal: Blood
Blood (2021) 138 (Supplement 1): 4398.
https://doi.org/10.1182/blood-2021-149261
Published: 2021
Journal Articles

Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)

Guillaume Richard-Carpentier, MD, Hagop M. Kantarjian, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Joseph D. Khoury, MD, Farhad Ravandi, MD, Nicholas J. Short, MD, Rita Khouri, Koichi Takahashi, MD, Maro Ohanian, DO, Gautam M. Borthakur, MD, Marina Y Konopleva, MD PhD, Naval G. Daver, MD, Zeev E. Estrov, MD, Yesid Alvarado, MD, Nitin Jain, MD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Michelle Velasquez, RN, Patrice Nasnas, MD, Susan O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1299.
https://doi.org/10.1182/blood-2019-130283
Published: 2019
Journal Articles

Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocytic Leukemia with Positive Minimal/Measurable Residual Disease

Iman Aboudalle, MD, Hagop M. Kantarjian, MD, Nicholas J Short, MD, Maria Khouri, Koichi Takahashi, MD, Maro N. Ohanian, DO, Gautam Borthakur, MD, Marina Y. Konopleva, MD PhD, Naval G. Daver, MD, Zeev E. Estrov, MD, Yesid Alvarado, MD, Nitin Jain, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Michelle Velasquez, RN, Patrice Nasnas, MD, Susan M. O'Brien, MD, Elias J. Jabbour, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5212.
https://doi.org/10.1182/blood-2018-99-119685
Published: 2018
Journal Articles

Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

Naval G. Daver, MD, Rita Assi, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Marina Y. Konopleva, MD PhD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Elias J. Jabbour, MD, Courtney D. DiNardo, MD MSc, Michelle Velasquez, RN, Mary Kelly, Jing Ning, PhD, Graciela M. Nogueras González, MPH, Sherry A. Pierce, BSN, BA, Dan Gombos, MD, Zeev E. Estrov, MD, Steven M. Kornblau, MD, Weiguo Zhang, MD PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1441.
https://doi.org/10.1182/blood-2018-99-118028
Published: 2018